The use of factor IX concentrates in man: a 9-year experience of Scottish concentrates in the South-East of Scotland.
During the last 9 years, two factor IX concentrates produced in Scotland, PPSB and DEFIX, have been used for the treatment of haemophilia B and acquired coagulation disorders, including those due to liver disease, coumarin therapy, neonatal immaturity and post-operative bleeding. During the period of study 112 batches of DEFIX and 40 batches of PPSB were used in the Edinburgh and South-East Scotland Region. Data were analysed from 575 non-haemophilic patients, receiving 968 treatment episodes, as well as 24 haemophiliacs. Serial coagulation studies and analysis of retrospective data showed that both concentrates corrected the coagulation deficiencies in all the above patient groups; in no case was there any evidence of intravascular coagulation resulting from concentrate infusion.
D001778:Blood Coagulation Disorders / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D001780:Blood Coagulation Tests; D003374:Coumarins / Q000506:poisoning; D005164:Factor IX / Q000627:therapeutic use*; D002836:Hemophilia B / Q000628:therapy*; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000188:drug therapy; D008107:Liver Diseases / Q000150:complications; D011446:Prospective Studies; D012189:Retrospective Studies; D012606:Scotland
D003374:Coumarins; D005164:Factor IX